Diagnosis of myelodysplastic syndromes after cytotoxic therapy for acute myeloid leukemia in the era of molecular research, difficulties in risk stratification and choice of therapy: The first domestic case report and literature review
https://doi.org/10.17650/1726-9784-2023-22-4-28-34
Abstract
Diagnosis of secondary myeloid neoplasms (therapy-related myeloid neoplasms) associated with therapy of solid tumors, in most cases, is not associated with significant difficulties. The problem is the diagnosis of secondary myelodysplastic syndromes after the treatment of acute myeloid leukaemias. The complexity of early diagnosis of secondary myelodysplastic syndromes is due to the differentiation of this nosology and the early recurrence of previous acute myeloid leukemia and, as a result, the difficulties of prognosis and risk stratification for therapeutic management. The relevance of this problem is explained by the rare case reports. Making the diagnosis of secondary myelodysplastic syndrome, in our opinion, can be based on the absence of a connection of cancer cell clone with the first (previous) disease in a molecular study. In this publication, we describe the first domestic case report of myelodysplastic syndrome diagnosed after chemotherapy for acute myeloid leukemia, based on differences in cytomorphology, immunophenotyping and molecular research. we interpreted the prognosis as favorable and prescribed appropriate treatment.
About the Authors
A. D. Shirin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
A. S. Antipova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
O. Yu. Baranova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
1A Ostrovityanova St., Moscow 117997
A. M. Ibragimov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
References
1. Schmiegelow K., Levinsen M.F., Attarbaschi A. et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2013;31(19):2469–76. DOI: 10.1200/JCO.2012.47.0500. PMID: 23690411
2. Pui C.H., Ribeiro R.C., Hancock M.L. et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325(24):1682–7. DOI: 10.1056/NEJM199112123252402
3. Makhacheva F.A., Valiev T.T. Clinical features of secondary acute myeloid leukemia in children. Onkogematologiya = Oncohematology 2020;15(4):12–7 (In Russ.) DOI: 10.17650/1818-8346-2020-15-4-12-17
4. Khan S.R., Tariq M., Fayyaz S.M. et al. Lenalidomide induced secondary acute lymphoblastic leukemia in a multiple myeloma patient: A case-report. Leuk Res Rep 2022;17:100315. DOI: 10.1016/j.lrr.2022.100315
5. Shivakumar R., Tan W., Wilding G.E. et al. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia – A review of 101 cases. Ann Oncol 2008;19(9):1634–8. DOI: 10.1093/annonc/mdn182
6. Zuna J., Cavé H., Eckert C. et al. Childhood secondary ALL after ALL treatment. Leukemia 2007;21(7):1431–5. DOI: 10.1038/sj.leu.2404718
7. Xie W., Chen Z., Wang S.A. et al. Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/ myeloproliferative neoplasms. Leuk Lymphoma 2019;60(12):2993–3001. DOI: 10.1080/10428194.2019.1605509
8. Martínez-Cuadrón D., Megías-Vericat J.E., Serrano J. et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: A PETHEMA registry study. Blood Adv 2022;6(4):1278–95. DOI: 10.1182/bloodadvances.2021005335
9. Szczepanski T., Willemse M.J., Kamps W.A. et al. Molecular discrimination between relapsed and secondary acute lymphoblastic leukemia: proposal for an easy strategy. Med Pediatr Oncol 2001;36(3):352–8. DOI: 10.1002/mpo.1085
10. Greenberg P., Cox C., LeBeau M.M. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079–88. DOI: 10.1182/blood.V89.6.2079
11. Greenberg P.L., Tuechler H., Schanz J. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120(12):2454–65. DOI: 10.1182/blood-2012-03-420489
12. Malcovati L., Germing U., Kuendgen A. et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25(23):3503–10. DOI: 10.1200/JCO.2006.08.5696
13. Kantarjian H., O’Brien S., Ravandi F. et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113(6):1351–61. DOI: 10.1002/cncr.23697
14. Kuendgen A., Nomdedeu M., Tuechler H. et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub- classification and risk-stratification – an approach to classification of patients with t-MDS. Leukemia 2021;35(3):835–49. DOI: 10.1038/s41375-020-0917-7
15. Sangiorgio V., Calaminici M. Therapy related myeloid neoplasm (therapy related AML). PathologyOutlines.com website. Available at: https://www.pathologyoutlines.com/topic/ bonemarrowneoplastictherapy.html. Accessed: 25.10.2022.
16. Khoury J.D., Solary E., Abla O. et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: Myeloid and histiocytic dendritic neoplasms. Leukemia 2022;36(7):1703–19. DOI: 10.1038/s41375-022-01613-1
17. Shih A.H., Chung S.S., Dolezal E.K. et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 2013(7);98(6):908–12. DOI: 10.3324/haematol.2012.076729
18. Churpek J.E., Larson R.A. The evolving challenge of therapy- related myeloid neoplasms. Best Pract Res Clin Haematol 2013;26(4):309–17. DOI: 10.1016/j.beha.2013.09.001
19. Rowley J.D., Olney H.J. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: Overview report. Genes Chromosomes Cancer 2002;33(4):331–45. DOI: 10.1002/gcc.10040
Review
For citations:
Shirin A.D., Antipova A.S., Baranova O.Yu., Ibragimov A.M. Diagnosis of myelodysplastic syndromes after cytotoxic therapy for acute myeloid leukemia in the era of molecular research, difficulties in risk stratification and choice of therapy: The first domestic case report and literature review. Russian Journal of Biotherapy. 2023;22(4):28-34. (In Russ.) https://doi.org/10.17650/1726-9784-2023-22-4-28-34
Views:
224
Email this article 
